Update October 13th: Thank you for your interest in collaborating with the COVID-19 Therapeutics Accelerator. We are not accepting new proposals at this time, but please check back in the future for updates on grant opportunities.  

The COVID-19 Therapeutics Accelerator has prioritized proposals based on the following scoping criteria. Solutions should have suitability for low-resource settings, with global access through prompt launch, and affordability in low- and middle-income countries (LMIC) with a focus on vulnerable populations.  

Nature of product 

Focus on therapeutics and select accompanying diagnostics;

In scope

  • Therapeutics (as further outlined below)
  • Diagnostics – rapid diagnostics to accompany therapeutics

Out of scope

  • Vaccines 
  • Personal protective equipment

Therapeutic use case 

Focus on prophylaxis and early disease treatment;

In scope

  • High pre-exposure prophylaxis (e.g. health workers)
  • High risk post-exposure prophylaxis (e.g. close contacts)
  • Mild disease treatment (outpatient)
  • Moderate disease treatment (early hospitalization)

Out of scope

  • Severe disease treatment (hospitalized, likely requiring oxygen supplementation)
  • Critical disease treatment (ICU, ventilated) with indications such as acute respiratory distress syndrome (ARDS) or cytokine release storm

Therapeutic modality 

Focus on small molecules (antiviral and nonantiviral) and virus-neutralizing antibodies appropriate for early disease treatment;

In scope

  • Small molecule drugs: includes both antivirals and non-antiviral small molecule drugs that are host-directed (but applicable in early disease)
  • Monoclonal antibodies (mAbs): both virus neutralizing antibodies and other mAbs/biologics
  • Polyclonal antibodies / plasma-related therapies: virus neutralizing antibodies and plasma

Out of scope

  • Cell, gene and RNA therapy 
  • Traditional Chinese Medicines; vitamins and supplements